arrow
B

Bruce R. Korf

University of Alabama at Birmingham
H指数:77
被引数:2.6万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Advancing the science of genomic learning healthcare systems

推进基因组学习型医疗系统的科学

2025-07-230
OA
Effect of bevacizumab on non-target intracranial meningiomas and non-vestibular schwannomas in NF2-related schwannomatosis: NF104

贝伐单抗对NF2相关性神经鞘瘤病中非靶点颅内脑膜瘤和非前庭神经鞘瘤的影响:NF104

2025-05-280
PRE
Treatment of Cutaneous Neurofibromas in Neurofibromatosis Type 1 With MEK Inhibitor Selumetinib A Nonrandomized Clinical Trial

神经纤维瘤病1型皮肤神经纤维瘤的MEK抑制剂Selumetinib治疗:一项非随机临床试验

2025-02-260
PRE
The BabySeq Project: A clinical trial of genome sequencing in a diverse cohort of infants
2024-10-013
PRE
snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response
2024-06-211
OAAI
Parents' Perspectives on the Utility of Genomic Sequencing in the Neonatal Intensive Care Unit
2023-06-213
OAAI
Comparison of a STIR- and T1-based radiomics model to differentiate between plexiform neurofibromas and malignant peripheral nerve sheath tumors in neurofibromatosis type 1 (NF1)
2023-04-251
PRE
Multicenter, prospective, phase II study of maintenance bevacizumab for children and adults with NF2-related schwannomatosis and progressive vestibular schwannoma

贝伐单抗维持治疗儿童和成人NF2-related神经鞘瘤病和进行性前庭神经鞘瘤的多中心,前瞻性,II期研究

2023-04-039
OAAI
Returning integrated genomic risk and clinical recommendations: The eMERGE study

回归综合基因组风险和临床建议: eMERGE研究

2023-04-0145
OAAI
Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: An international consensus recommendation

更新2型神经纤维瘤病和神经鞘瘤病的诊断标准和术语: 国际共识推荐

2022-09-0190
OA